Abstract: Non-small cell lung cancer (NSCLC) accounts for 85% of total cases of lung cancer, which has the highest incidence and mortality in China. Most patients with lung cancer present with advanced stage disease at the time of diagnosis. With the limited development of cytotoxic chemotherapy for NSCLC therapy, median overall survival in patients receiving platinum-based doublet chemotherapy has been less than one year in several trials. To date, anti-angiogenesis agents combined with chemotherapy, small molecule tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors were commonly applied in NSCLC instead of purely chemotherapy, which makes a great breakthrough in NSCLC therapy. This review summarizes and discusses the application of anti-angiogenic therapy in advanced NSCLC.